Related references
Note: Only part of the references are listed.Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B
Norah S. Terrault et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2023)
Getting to HBV cure: The promising paths forward
Scott Fung et al.
HEPATOLOGY (2022)
Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT
Seng Gee Lim et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study)
Grishma Hirode et al.
GASTROENTEROLOGY (2021)
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naive to Nucleos(t)ide Therapy
Michel Bazinet et al.
GASTROENTEROLOGY (2020)
Systematic review with meta-analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance
K. Qiu et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
Norah A. Terrault et al.
HEPATOLOGY (2018)
Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis
Sang Hoon Ahn et al.
DIGESTIVE DISEASES AND SCIENCES (2018)
Combination of Tenofovir Disoproxil Fumarate and Peginterferon alpha-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B
Patrick Marcellin et al.
GASTROENTEROLOGY (2016)